On the sell side, Jayanti Sinha sold 12.38 lakh shares, while Samprada & Nanhamati Singh Family Trust offloaded 5.5 lakh shares. Together, the two sellers divested 17.88 lakh shares. The shares were acquired by a mix of domestic and foreign institutional investors.
Among the largest buyers were ICICI Prudential Mutual Fund, which purchased 9.04 lakh shares, and HDFC Mutual Fund, which bought 5.1 lakh shares. Other participants included DSP Mutual Fund, Nippon India Mutual Fund, Morgan Stanley Asia Singapore, Goldman Sachs Bank Europe, BNP Paribas Arbitrage, Societe Generale and Edelweiss Mutual Fund.
The deal comes after a strong run in Alkem Laboratories shares over the past year, supported by steady growth in its domestic formulations business, improving margins and a recovery in its US operations.
Alkem is among India’s leading pharmaceutical companies with a strong presence in acute therapies, chronic segments and international markets. The participation of large domestic mutual funds in the transaction suggests continued institutional interest in quality healthcare names despite broader market volatility.
Shares of Alkem Laboratories are likely to remain in focus as investors assess the impact of the stake sale and changes in promoter shareholding following the transaction.
